Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Consensus Rating of “Hold” from Brokerages

Shares of Satellos Bioscience Inc. (NASDAQ:MSLE) have been assigned an average recommendation of “Hold” from the five analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $15.50.

MSLE has been the subject of several research analyst reports. Cantor Fitzgerald initiated coverage on shares of Satellos Bioscience in a report on Wednesday, March 11th. They issued an “overweight” rating for the company. HC Wainwright raised their price objective on shares of Satellos Bioscience to $11.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Zacks Research upgraded shares of Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Wall Street Zen lowered shares of Satellos Bioscience to a “strong sell” rating in a report on Saturday, March 14th. Finally, Leerink Partners initiated coverage on shares of Satellos Bioscience in a report on Monday, April 6th. They issued an “outperform” rating and a $20.00 price objective for the company.

Satellos Bioscience Trading Up 4.8%

Satellos Bioscience stock opened at $6.50 on Monday. The business’s 50-day moving average price is $9.01. The stock has a market capitalization of $135.40 million, a price-to-earnings ratio of -4.19 and a beta of 1.37. Satellos Bioscience has a 1-year low of $4.53 and a 1-year high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last posted its earnings results on Friday, March 27th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.11).

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.